Overview

Price chart · mood · technical indicators

CBIO

Crescent Biopharma, Inc.stock Healthcare

Biotechnology

$17.9212.00%Current Market Mood:Bullish

Market Mood

Price Range (1Y)

$8.72$27.41

Current: $17.92

Market Comparison

vs Healthcare Sector & Biotechnology Industry

CBIO

+12.00%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—

EPS (TTM)$-5.320.0% YoY

Profit margin0.0%HEALTHCARE

Market cap$550.4MSmall cap

Wall Street coverage

$29.29median target· current $16.00 (+83.1%)9 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: —
PEG ratio: —
P/B: 3.06
P/S (TTM): 50.76
EV/EBITDA: —

Profitability & growth

ROE (TTM): -160.7%
Operating margin: -844.0%
Revenue growth YoY: 0.0%
Dividend yield: —
Beta: —

Last earnings

Mar 31, 2026 · Estimate $-0.79 · Reported $-0.70

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Crescent Biopharma, Inc.

Company profile

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, is focused on developing candidates for protease products in the fields of hemostasis and complement regulation. The company is headquartered in South San Francisco, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 300 FIFTH AVENUE, WALTHAM, MA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$550.4M

Shares outstanding$27.6M

52W high$29.00

52W low$8.72

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

CBIO

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Crude Oil Down 3%; Chevron Posts Mixed Q1 Results

Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue

Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk

Crescent lines up 2027 cancer trial readouts with cash into 2028

Crescent Biopharma (NASDAQ: CBIO) posts Q1 2026 loss and oncology pipeline update

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?

CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC

Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan

New Crescent hires receive stock options priced at Nasdaq's $25.70 close

CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Form DEFA14A CRESCENT BIOPHARMA, INC.

Crescent Biopharma (NASDAQ: CBIO) outlines 2026 AGM votes on board, pay and auditor

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35

Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree

Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree

About Crescent Biopharma, Inc.

Classification

Company profile

CBIO

Market Comparison

CBIO Market Analysis

Overview

CBIO

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Crude Oil Down 3%; Chevron Posts Mixed Q1 Results

Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue

Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk

Crescent lines up 2027 cancer trial readouts with cash into 2028

Crescent Biopharma (NASDAQ: CBIO) posts Q1 2026 loss and oncology pipeline update

Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving Average - Should You Sell?

CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC

Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan

New Crescent hires receive stock options priced at Nasdaq's $25.70 close

CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Crescent Biopharma Announces Grants of Inducement Awards

Form DEFA14A CRESCENT BIOPHARMA, INC.

Crescent Biopharma (NASDAQ: CBIO) outlines 2026 AGM votes on board, pay and auditor

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts

Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35

Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree

Crescent Biopharma Stock Surges 85%, With A 6-Day Winning Spree

About Crescent Biopharma, Inc.

Classification

Company profile

CBIO

Market Comparison